<DOC>
	<DOCNO>NCT02525250</DOCNO>
	<brief_summary>This project framework develop new therapeutic strategy acute myeloid leukemia ( AML ) base immunotherapy . role NK cell demonstrate AML especially GVL effect ( graft versus leukemia ) allogeneic transplantation patient . However , show phenotype NK cell cytotoxic function alter malignancy . In addition , patient , impaired NK function associate relapse . lenalidomide would beneficial effect NK cell AML patient ? Does role leukemic cell malignancy ? effect production pro-inflammatory cytokine ? In vitro data show effect lenalidomide phenotype NK cell healthy donor patient LAM , despite phenotypic change , cytotoxic capacity NK altered.Lenalidomide also induce significant increase production TNF-alpha ( tumor necrosis factor ) NK . It also seem effect leukemic blast AML . So , investigator hope study confirm result vivo peripheral blood cell patient treat lenalidomide .</brief_summary>
	<brief_title>Pilot Study Immunomonitoring Natural Killers Cells Patients With Myeloid Malignancies Treated With Lenalidomide</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<criteria>Patient age 18 year , Patient myeloid acute leukemia myelodysplasic syndrome , treat treat Revlimid , Signed consent participate , Patient affiliate social security system benefit system . Allogeneic patient beyond , Patient deprive liberty supervision guardian , Impossibility undergo medical examination study geographical , social psychological reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Acute myeloid leukemia myelodysplasic syndrome</keyword>
</DOC>